ENXTBR:ARGXBiotechs
argenx (ENXTBR:ARGX) Hits A Phase 3 Win, Is The Upside Fully Priced?
argenx (ENXTBR:ARGX) is back in focus after reporting that the ALKIVIA Phase 3 trial of VYVGART Hytrulo in adults with autoimmune myositis met its primary endpoint, with clinically meaningful and statistically significant improvements.
See our latest analysis for argenx.
The positive ALKIVIA trial update comes on top of recent momentum in argenx, with a 7 day share price return of 17.34% and a 1 year total shareholder return of 53.68%, alongside a 5 year total shareholder return above...